{"protocolSection": {"identificationModule": {"nctId": "NCT02066129", "orgStudyIdInfo": {"id": "AsthmaNet 008"}, "organization": {"fullName": "Milton S. Hershey Medical Center", "class": "OTHER"}, "briefTitle": "Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations", "officialTitle": "Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations", "acronym": "STICS"}, "statusModule": {"statusVerifiedDate": "2018-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-07"}, "primaryCompletionDateStruct": {"date": "2017-04-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-04-21", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-17", "studyFirstSubmitQcDate": "2014-02-17", "studyFirstPostDateStruct": {"date": "2014-02-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-04-23", "resultsFirstSubmitQcDate": "2018-06-11", "resultsFirstPostDateStruct": {"date": "2018-07-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-06-11", "lastUpdatePostDateStruct": {"date": "2018-07-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "dave mauger", "investigatorTitle": "Principal Investigator, AsthmaNet Data Coordinating Center", "investigatorAffiliation": "Milton S. Hershey Medical Center"}, "leadSponsor": {"name": "Milton S. Hershey Medical Center", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The objective of this study is to determine whether, in children receiving low-dose inhaled corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations reduces the rate of severe asthma exacerbations treated with oral corticosteroids.", "detailedDescription": "The study design is a double-blind, parallel-group trial, including a total of 250 participants, ages 5-11 years, with a diagnosis of asthma and a history of at least 1 asthma exacerbation treated with oral corticosteroids in the prior year. All participants will be treated for 48 weeks with open-label fluticasone 44 mcg 2 puffs twice daily. During the 48-week treatment period, participants will receive randomized blinded therapy for 7 days each time they enter the \"yellow zone\" (at the onset of symptoms previously associated with upper respiratory illnesses and subsequent asthma exacerbations). Yellow zone therapy will be fluticasone 44 or 220 mcg 2 puffs twice daily."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Fluticasone"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 254, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fluticasone 44 mcg", "type": "ACTIVE_COMPARATOR", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.", "interventionNames": ["Drug: Fluticasone 44 mcg"]}, {"label": "Fluticasone 220 mcg", "type": "ACTIVE_COMPARATOR", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.", "interventionNames": ["Drug: Fluticasone 220 mcg"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone 44 mcg", "description": "Fluticasone is an inhaled corticosteroid", "armGroupLabels": ["Fluticasone 44 mcg"], "otherNames": ["Flovent\u00ae 44 mcg"]}, {"type": "DRUG", "name": "Fluticasone 220 mcg", "description": "Fluticasone is an inhaled corticosteroid", "armGroupLabels": ["Fluticasone 220 mcg"], "otherNames": ["Flovent\u00ae 220 mcg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Asthma Exacerbations", "description": "The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.", "timeFrame": "end of 48 week treatment period"}], "secondaryOutcomes": [{"measure": "Yellow Zone Asthma Symptoms", "description": "Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days.", "timeFrame": "end of 48 week treatment period"}, {"measure": "Yellow Zone Albuterol Use", "description": "Use of albuterol rescue medication during 7-day yellow zone episodes.", "timeFrame": "end of 48 week treatment period"}, {"measure": "Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma", "description": "Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period.", "timeFrame": "end of 48 week treatment period"}, {"measure": "Number of Participants Hospitalized for Asthma", "description": "Number of participants hospitalized for asthma during the 48 week treatment period.", "timeFrame": "end of 48 week treatment period"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Physician-diagnosed asthma\n* At least 1 exacerbation treated with systemic (oral or injectable) corticosteroids in the past 12 months\n* Able to perform reproducible spirometry\n* Current treatment with step 2 controller therapy \\[low-dose ICS, leukotriene receptor antagonist (LTRA)\\] OR current treatment with step 3 controller therapy \\[low-dose ICS + long-acting beta agonist (LABA), low-dose ICS + LTRA, or medium dose ICS\\] with a childhood Asthma Control Test (c-ACT) score of \\>19, no more than 2 prednisone treated exacerbations in the past 6 months, prebronchodilator Forced Expiratory Volume at 1 second (FEV1) \u2265 80% predicted and willing to step down therapy OR controller na\u00efve and qualifying for step 2 controller therapy \\[asthma symptoms or short acting beta agonist (SABA) use \\> 2 days per week or night-time awakenings due to asthma \\> 2 nights per month\\]\n* Prebronchodilator FEV1 \u2265 60% predicted\n* Ability and willingness to provide informed assent\n* For females of childbearing potential: not pregnant, non-lactating, and agree to practice an adequate birth control method.\n* History of clinical varicella or varicella vaccine\n\nExclusion Criteria:\n\n* Systemic (oral or injectable) corticosteroids within previous 2-week period\n* Current or recent (previous 2-weeks) use of medications known to significantly interact with corticosteroid disposition, including but not limited to carbamazepine, erythromycin, phenobarbital, phenytoin, rifampin, and ketoconazole\n* Presence of chronic or active lung disease other than asthma\n* Significant medical illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical problems that could require oral corticosteroids during the study\n* A history of cataracts, glaucoma, or any other medical disorder associated with an adverse effect to corticosteroids\n* History of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure\n* More than 5 prednisone treated exacerbations in the past 12 months\n* More than 1 hospitalizations lasting \\>24 hours for asthma in the past 12 months\n* History of adverse reactions to ICS preparations or any of their ingredients\n* Receiving hyposensitization therapy other than an established maintenance regimen (On maintenance regimen for \u2265 3 months)\n* History of premature birth before 35 weeks gestation", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "5 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "William Busse, MD", "affiliation": "University of Wisconsin, Madison", "role": "STUDY_CHAIR"}], "locations": [{"facility": "University of Arizona College of Medicine", "city": "Tucson", "state": "Arizona", "zip": "85724", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Children's Hospital & Research Center Oakland", "city": "Oakland", "state": "California", "zip": "94609", "country": "United States", "geoPoint": {"lat": 37.80437, "lon": -122.2708}}, {"facility": "UCSF Benioff Children's Hospital", "city": "San Francisco", "state": "California", "zip": "94143", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "National Jewish Health", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Nemours Children's Clinic", "city": "Jacksonville", "state": "Florida", "zip": "32207", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Nemours Children's Clinic", "city": "Orlando", "state": "Florida", "zip": "32827", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Rush University Medical Center/Stroger Hospital", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University of Illinois at Chicago", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Ann and Robert H. Lurie Children's Hospital", "city": "Chicago", "state": "Illinois", "zip": "60614", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Children's Hospital Boston", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "St. Louis Children's Hospital", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Washington University", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Wake Forest University Health Sciences", "city": "Winston-Salem", "state": "North Carolina", "zip": "27157", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Rainbow Babies and Children's Hospital, Case Western Reserve University", "city": "Cleveland", "state": "Ohio", "zip": "44106", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Allegheny General Hospital", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Children's Hospital of Pittsburgh of UPMC", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15224", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "University of Wisconsin", "city": "Madison", "state": "Wisconsin", "zip": "53972", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"references": [{"pmid": "29504498", "type": "DERIVED", "citation": "Jackson DJ, Bacharier LB, Mauger DT, Boehmer S, Beigelman A, Chmiel JF, Fitzpatrick AM, Gaffin JM, Morgan WJ, Peters SP, Phipatanakul W, Sheehan WJ, Cabana MD, Holguin F, Martinez FD, Pongracic JA, Baxi SN, Benson M, Blake K, Covar R, Gentile DA, Israel E, Krishnan JA, Kumar HV, Lang JE, Lazarus SC, Lima JJ, Long D, Ly N, Marbin J, Moy JN, Myers RE, Olin JT, Raissy HH, Robison RG, Ross K, Sorkness CA, Lemanske RF Jr; National Heart, Lung, and Blood Institute AsthmaNet. Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations. N Engl J Med. 2018 Mar 8;378(10):891-901. doi: 10.1056/NEJMoa1710988. Epub 2018 Mar 3."}], "seeAlsoLinks": [{"label": "AsthmaNet", "url": "http://asthmanetresearch.org/"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Fluticasone 44 mcg", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 44 mcg: Fluticasone is an inhaled corticosteroid"}, {"id": "FG001", "title": "Fluticasone 220 mcg", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 220 mcg: Fluticasone is an inhaled corticosteroid"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "127"}, {"groupId": "FG001", "numSubjects": "127"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "98"}, {"groupId": "FG001", "numSubjects": "94"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "29"}, {"groupId": "FG001", "numSubjects": "33"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Fluticasone 44 mcg", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 44 mcg: Fluticasone is an inhaled corticosteroid"}, {"id": "BG001", "title": "Fluticasone 220 mcg", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 220 mcg: Fluticasone is an inhaled corticosteroid"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "127"}, {"groupId": "BG002", "value": "254"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.9", "spread": "1.9"}, {"groupId": "BG001", "value": "8.1", "spread": "1.8"}, {"groupId": "BG002", "value": "8.0", "spread": "1.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "91"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "80"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "163"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "140"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "56"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "58"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "127"}, {"groupId": "BG002", "value": "254"}]}]}]}, {"title": "Blood eosinophils", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cells per cubic millimeter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "367", "spread": "300"}, {"groupId": "BG001", "value": "327", "spread": "234"}, {"groupId": "BG002", "value": "346", "spread": "268"}]}]}]}, {"title": "Number of positive allergen specific IgE tests", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "count", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.8", "spread": "4.2"}, {"groupId": "BG001", "value": "5.2", "spread": "4.5"}, {"groupId": "BG002", "value": "5.0", "spread": "4.4"}]}]}]}, {"title": "Hospitalized in year prior to enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Post albuterol forced expiratory volume at one second (FEV1) % of predicted", "description": "FEV1 following 4 puffs of albuterol, expressed as percent of predicted (based on age, sex, race, and height).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "106.8", "spread": "15.6"}, {"groupId": "BG001", "value": "107.8", "spread": "13.9"}, {"groupId": "BG002", "value": "107.3", "spread": "14.8"}]}]}]}, {"title": "At least one allergen specific immunoglobulin E (IgE) tests", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "88"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "187"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Asthma Exacerbations", "description": "The primary outcome is the rate of severe asthma exacerbations treated with oral corticosteroids during the 48 week treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "exacerbations per year", "timeFrame": "end of 48 week treatment period", "groups": [{"id": "OG000", "title": "Fluticasone 44 mcg", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 44 mcg: Fluticasone is an inhaled corticosteroid"}, {"id": "OG001", "title": "Fluticasone 220 mcg", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 220 mcg: Fluticasone is an inhaled corticosteroid"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.37", "lowerLimit": "0.25", "upperLimit": "0.55"}, {"groupId": "OG001", "value": "0.48", "lowerLimit": "0.33", "upperLimit": "0.70"}]}]}]}, {"type": "SECONDARY", "title": "Yellow Zone Asthma Symptoms", "description": "Study participants completed a daily symptom diary. They scored the following diary elements on a scale from 0-3 (none-severe): Cough, Wheeze, Trouble Breathing, Interference With Activities. A combined score was calculated as the sum of the 4 elements and ranged from 0 to 12. The study intervention was based on yellow-zones as noted in the Study Description. This outcome was based on diary data including 21 days, beginning 7 days prior to the onset of the yellow-zone intervention and ending 14 days after the onset of the intervention. The total symptom burden outcome was defined as the sum of the combined score on each diary day and ranged from 0 to 252 (max combined score of 12 per day multiplied by 21 days). A score of zero would indicate no symptoms over the entire 21 days. A score of 252 would indicate severe cough, wheeze, shortness of breath, and interference with activities on all of the 21 days.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "end of 48 week treatment period", "groups": [{"id": "OG000", "title": "Fluticasone 44 mcg", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 44 mcg: Fluticasone is an inhaled corticosteroid"}, {"id": "OG001", "title": "Fluticasone 220 mcg", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 220 mcg: Fluticasone is an inhaled corticosteroid"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20", "lowerLimit": "17", "upperLimit": "24"}, {"groupId": "OG001", "value": "23", "lowerLimit": "19", "upperLimit": "27"}]}]}]}, {"type": "SECONDARY", "title": "Yellow Zone Albuterol Use", "description": "Use of albuterol rescue medication during 7-day yellow zone episodes.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "number of albuterol puffs", "timeFrame": "end of 48 week treatment period", "groups": [{"id": "OG000", "title": "Fluticasone 44 mcg", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 44 mcg: Fluticasone is an inhaled corticosteroid"}, {"id": "OG001", "title": "Fluticasone 220 mcg", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 220 mcg: Fluticasone is an inhaled corticosteroid"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13", "lowerLimit": "11", "upperLimit": "16"}, {"groupId": "OG001", "value": "15", "lowerLimit": "13", "upperLimit": "19"}]}]}]}, {"type": "SECONDARY", "title": "Unscheduled Emergency Department (ED) or Urgent Care Visits for Asthma", "description": "Rate of emergency department (ED) or urgent care visits for asthma during the 48 week treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "visits per year", "timeFrame": "end of 48 week treatment period", "groups": [{"id": "OG000", "title": "Fluticasone 44 mcg", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 44 mcg: Fluticasone is an inhaled corticosteroid"}, {"id": "OG001", "title": "Fluticasone 220 mcg", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 220 mcg: Fluticasone is an inhaled corticosteroid"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.47", "lowerLimit": "0.31", "upperLimit": "0.72"}, {"groupId": "OG001", "value": "0.64", "lowerLimit": "0.42", "upperLimit": "0.96"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Hospitalized for Asthma", "description": "Number of participants hospitalized for asthma during the 48 week treatment period.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "end of 48 week treatment period", "groups": [{"id": "OG000", "title": "Fluticasone 44 mcg", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 44 mcg: Fluticasone is an inhaled corticosteroid"}, {"id": "OG001", "title": "Fluticasone 220 mcg", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 220 mcg: Fluticasone is an inhaled corticosteroid"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "48 weeks", "eventGroups": [{"id": "EG000", "title": "Fluticasone 44 mcg", "description": "Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 44 mcg: Fluticasone is an inhaled corticosteroid", "deathsNumAffected": 0, "deathsNumAtRisk": 127, "seriousNumAffected": 1, "seriousNumAtRisk": 127, "otherNumAffected": 115, "otherNumAtRisk": 127}, {"id": "EG001", "title": "Fluticasone 220 mcg", "description": "Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of \"yellow zone\" symptoms.\n\nFluticasone 220 mcg: Fluticasone is an inhaled corticosteroid", "deathsNumAffected": 0, "deathsNumAtRisk": 127, "seriousNumAffected": 4, "seriousNumAtRisk": 127, "otherNumAffected": 111, "otherNumAtRisk": 127}], "seriousEvents": [{"term": "Asthma Exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 127}]}, {"term": "Hypertrophy Tonsils/Adenoids", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 127}]}], "otherEvents": [{"term": "Otitis media", "organSystem": "Nervous system disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 14, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 20, "numAffected": 14, "numAtRisk": 127}]}, {"term": "Acute nasopharyngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 99, "numAffected": 46, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 57, "numAffected": 33, "numAtRisk": 127}]}, {"term": "Acute respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 39, "numAffected": 22, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 41, "numAffected": 21, "numAtRisk": 127}]}, {"term": "Acute sinusitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 9, "numAffected": 7, "numAtRisk": 127}]}, {"term": "Allergic rhinitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 62, "numAffected": 36, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 45, "numAffected": 28, "numAtRisk": 127}]}, {"term": "Infectious enteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 127}]}, {"term": "Strep sore throat", "organSystem": "Infections and infestations", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 16, "numAffected": 10, "numAtRisk": 127}]}, {"term": "Cough", "organSystem": "General disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 45, "numAffected": 29, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 49, "numAffected": 30, "numAtRisk": 127}]}, {"term": "Fever", "organSystem": "General disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 39, "numAffected": 24, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 28, "numAffected": 21, "numAtRisk": 127}]}, {"term": "Headache", "organSystem": "General disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 15, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 12, "numAffected": 10, "numAtRisk": 127}]}, {"term": "Throat pain", "organSystem": "General disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 127}]}, {"term": "Vomiting alone", "organSystem": "General disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 8, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 14, "numAffected": 10, "numAtRisk": 127}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 8, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 8, "numAffected": 6, "numAtRisk": 127}]}, {"term": "Acute asthma attack", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "ICD-9", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 32, "numAffected": 25, "numAtRisk": 127}, {"groupId": "EG001", "numEvents": 37, "numAffected": 30, "numAtRisk": 127}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "David Mauger, PhD", "organization": "Penn State University Dept of Public Health Sciences", "email": "dmauger@psu.edu", "phone": "717.531.3584"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2015-03-16", "uploadDate": "2018-04-23T20:42", "filename": "Prot_SAP_000.pdf", "size": 1458072}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}